Long-term Virologic Suppression Despite Presence of Resistance-associated Mutations Among Perinatally HIV-infected Youth. Issue 12 (December 2015)

• Record Type: Journal Article
• Authors: Smith, Tiffeny T.; Hsu, Alice J.; Hutton, Nancy; Womble, Faith; Agwu, Allison L.
• Is Part Of: Pediatric infectious disease journal. Volume 34:Issue 12(2015)
• Publication Date: 2015-12
• Subjects: HIV -- antiretroviral -- perinatal infection; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000000895
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : Background: There is limited information on long-term consequences of continuing combination antiretroviral therapy (cART) consisting of <3 active drugs in treatment-experienced youth with perinatal HIV (PHIV). This study describes the clinical outcomes of PHIV youth who maintained virologic suppression (VS) for ≥1 year despite receiving cART with <3 active agents. Methods: A retrospective cohort study was conducted to quantify the duration of VS (viral load < 400 copies/mL), and using Cox proportional hazards regression, we identify factors associated with the primary outcome of virologic breakthrough (VB). Results: Thirty-seven patients were included. The median age, baseline CD4 count and HIV RNA viral load were 14 years, 477 cells/mm 3 and 2920 copies/mL, respectively. All patients harbored reverse transcriptase, and 57% harbored protease mutations. The median duration of VS was 37 months (interquartile range: 22–66). Fifteen patients (41%) had VB. The median change in CD4 count during VS was +82 cells/mm 3 at 12 months. The risk of VB was lower in those who gained ≥50 cells/mm 3 by 12 months (unadjusted hazards ratio: 0.271; 95% confidence interval: 0.0825–0.893; P, 0.032); however, this was not significant in the adjusted model. Conclusions: VS was maintained for a median of 3 years without decline in CD4 count. Independent risk factors for VB were not identified; however, there was a trend toward higher risk of VB in those without CD4 gain of ≥50 cells/mm 3 by 12 months. Suppressive cART containing <3 active agents could be an option in difficult to manage PHIV youth with close monitoring.